Low-Dose Testosterone for Women: FDA Status, Legal Challenges, and What the Label Actually Says

Why There Is No FDA-Approved Testosterone Product for Women in the US

The short answer: every attempt to get one approved has failed, not because testosterone does not work in women, but because regulators demanded long-term safety data that sponsors were unwilling or unable to fund. This leaves millions of women in a legal gray zone where clinically sound treatment exists but has no formal regulatory home.

The Intrinsa Story

The most detailed example is Intrinsa, a 300-mcg/day testosterone patch developed by Procter & Gamble specifically for surgically postmenopausal women with hypoactive sexual desire disorder (HSDD). Two Phase 3 trials, INTIMATE SM1 and INTIMATE SM2, showed statistically significant increases in satisfying sexual events compared with placebo. The FDA Reproductive and Urologic Drugs Advisory Committee voted 14 to 2 in December 2004 that the benefit-risk profile was favorable. The FDA still rejected the new drug application.

The agency's concern was not efficacy. The FDA asked for a dedicated cardiovascular and breast-cancer safety trial of at least five years' duration before it would approve the product for any female indication. Procter & Gamble withdrew the application rather than fund that trial. Intrinsa went on to receive European Medicines Agency (EMA) approval in 2006 for the same indication, but it was later withdrawn from European markets in 2012 because of poor commercial performance, not safety signals.

Why the Safety Trial Was Never Done

Funding a five-year cardiovascular and breast safety trial for a niche market product in an era before the global consensus had established the female testosterone evidence base was commercially unviable for most sponsors. The 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women, endorsed by 10 international societies including The Menopause Society and the International Society for the Study of Women's Sexual Health (ISSWSH), concluded that there is "sufficient evidence to support short-term safety" but acknowledged that data beyond 24 months remain sparse. That evidence gap is real, and it is one reason this article will not overstate what we know.

What About Male-Labeled Testosterone Products?

Male-labeled products, gels such as AndroGel and Testim, and injectable testosterone cypionate, carry no female indication. Prescribing them to women is legal as off-label use under the FDA's framework, but the doses formulated for men (typically 50 to 100 mg/day for hypogonadal men) are approximately 10 to 40 times higher than what a woman needs. Using a male product off-label requires careful compounding of the dose or precise application of a fraction of the packet, which introduces dosing inconsistency. Physicians who do this must document the clinical rationale clearly.

The Legal and Patent Field: Why Compounding Fills the Gap

Because no company holds an approved female indication, no patent exclusivity wall protects a single manufacturer. This is both a problem and a solution.

How Compounding Pharmacies Operate Legally

Compounding pharmacies that produce testosterone cream or gel for women operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding when a licensed practitioner writes a valid prescription. A 503A pharmacy does not need FDA approval for the finished product, but it must use FDA-registered bulk active pharmaceutical ingredients and must not produce drugs that are "essentially a copy" of an FDA-approved product in a way that undermines the approval process.

Section 503B covers outsourcing facilities that can produce larger batches without patient-specific prescriptions, subject to FDA registration and Current Good Manufacturing Practice (CGMP) inspections. Both categories are legal frameworks, but neither provides the safety and efficacy review that an NDA or ANDA does.

The "Essentially a Copy" Problem

The FDA has periodically flagged that compounded testosterone preparations for women could be considered copies of withdrawn or unapproved drugs, raising regulatory questions. As of 2025, FDA guidance on compounding has not explicitly placed testosterone on its list of drugs that cannot be compounded (the 503A "difficult to compound" or "demonstrably difficult" lists), so patient-specific prescriptions remain legally defensible. State pharmacy boards add another layer: rules vary considerably by state, and some states impose stricter requirements on testosterone compounding than others.

No Patent Holds the Female Indication

Because no product has ever been approved for women, no company holds a patent that would block a competitor from seeking its own approval. This cuts both ways. A pharmaceutical company could theoretically file a new NDA for a novel testosterone delivery system for women, and the FDA's 505(b)(2) pathway allows reliance on existing safety and efficacy data. Several companies have explored this. The commercial calculus remains challenging because the FDA's requirement for long-term cardiovascular and breast safety data has not changed since 2004.

The WomanRx Regulatory Gap Framework: The absence of an approved female testosterone product is not a finding that testosterone is unsafe for women. It reflects a specific regulatory-commercial mismatch: the FDA requires a large, long-duration safety trial; the market size for a prescription female testosterone product in the US does not currently justify that investment for most sponsors. Women, and their clinicians, should understand this distinction clearly. The evidence that exists, mostly from trials of 6 to 24 months, does not show increased cardiovascular events or breast cancer at female-range doses. The absence of certainty is not the same as evidence of harm.

What Existing Labels and Guidelines Actually Say

The Global Consensus Position Statement (2019)

The 2019 Global Consensus Position Statement, published simultaneously in the journals Climacteric, The Journal of Clinical Endocrinology and Metabolism, and others, is the closest thing to an authoritative clinical label for female testosterone use. It states:

"There is a biologic plausibility and reasonable evidence to support the use of testosterone for postmenopausal women with HSDD."

The statement recommends targeting physiologic premenopausal blood levels (free testosterone at the upper end of the normal premenopausal range), using transdermal delivery, and monitoring serum testosterone at 3 to 6 weeks, then 6 months. It explicitly advises against supraphysiologic dosing.

The consensus covers postmenopausal women specifically. For premenopausal women, the evidence base is insufficient to make a formal recommendation, and this is stated plainly in the document.

What the Male-Product Labels Say About Women

The package inserts for FDA-approved male testosterone products uniformly list women as a contraindicated population for the approved indication. For example, the AndroGel prescribing information states that the drug is contraindicated in women who are pregnant or may become pregnant and is not indicated for use in women at all under its approved labeling. Off-label use is a prescriber decision, not a label endorsement.

State-Level Prescribing Rules

No federal law prohibits a licensed physician from prescribing compounded testosterone to a woman. State medical boards govern prescribing practice. A handful of states have moved to restrict testosterone prescribing outside of endocrinology or urology, but most states permit any licensed physician to prescribe it with appropriate documentation of clinical indication.

Sex-Specific Pharmacology: Why Female Dosing Is Fundamentally Different

Women need roughly 300 mcg/day transdermally, approximately 1/10th to 1/40th of the doses used in hypogonadal men. This difference is not arbitrary.

Pharmacokinetics in Women

Testosterone in women undergoes the same hepatic metabolism (CYP3A4 predominant) and sex hormone-binding globulin (SHBG) binding as in men, but baseline production rates differ dramatically. Premenopausal women produce roughly 0.1 to 0.4 mg of testosterone daily from the ovaries and adrenal glands combined. After natural menopause, ovarian testosterone output falls by approximately 50%, and after surgical menopause (oophorectomy), the drop is more abrupt and pronounced. This context explains why the same 5 mg male gel packet can produce markedly supraphysiologic levels in a woman.

How the Menstrual Cycle Changes the Picture

In premenopausal women, testosterone levels fluctuate across the cycle, peaking around ovulation. A woman in her reproductive years who is considering testosterone should understand that measuring a trough level on day 2 of her cycle will produce a different result than measuring at midcycle, and that "low testosterone" in a premenopausal woman has a different clinical meaning than in a postmenopausal one. The Global Consensus explicitly states that evidence for testosterone use in premenopausal women is insufficient for a formal recommendation.

PCOS: A Special Case

Women with polycystic ovary syndrome (PCOS) typically have endogenous testosterone levels at or above the upper limit of the normal female range. Adding exogenous testosterone to a woman with PCOS is almost never indicated and could worsen androgenic symptoms including hirsutism, acne, and potentially metabolic parameters. Any evaluation for testosterone therapy must first rule out PCOS as a cause of androgen excess. ACOG Practice Bulletin 194 on PCOS is the relevant reference for the diagnostic workup.

Pregnancy, Lactation, and Contraception: Mandatory Safety Section

Testosterone is teratogenic. This is not a theoretical concern.

Pregnancy

Exogenous androgens given during pregnancy can cause virilization of a female fetus, including ambiguous genitalia. This risk is highest during the first trimester when fetal sex differentiation occurs, but androgen exposure carries risk throughout pregnancy. Testosterone carries a Pregnancy Category X designation under the legacy FDA system, meaning the risks outweigh any possible benefit. The current FDA Pregnancy and Lactation Labeling Rule (PLLR) replaces the letter categories for drugs approved after 2015, but the underlying teratogenicity data for testosterone are well established and the clinical conclusion is the same: testosterone is contraindicated in pregnancy.

Any woman of reproductive age who is prescribed testosterone must use reliable contraception. Because testosterone does not suppress ovulation reliably (it is not a contraceptive), pregnancy is possible even with testosterone use. Intrauterine devices (hormonal or copper) or barrier methods are commonly used alongside testosterone in premenopausal women. Providers must document contraception status and counseling at every prescription.

If you discover you are pregnant while using testosterone, stop immediately and contact your clinician. The prescriber should report the exposure to the FDA MedWatch system.

Lactation

Testosterone passes into breast milk. The degree of transfer and its clinical significance for a nursing infant have not been well studied, which is itself a concern. Given the lack of safety data and the biologic plausibility of androgen effects on a nursing infant's development, testosterone use during breastfeeding is not recommended. Women in the postpartum period who are breastfeeding should defer testosterone use until weaning. This guidance aligns with the precautionary principle applied broadly across hormone therapies in lactation.

Contraception Requirement Summary

| Situation | Recommendation | |---|---| | Reproductive-age woman on testosterone | Reliable non-testosterone contraception required | | Pregnancy discovered on testosterone | Stop testosterone immediately, notify prescriber | | Breastfeeding | Defer testosterone until weaning | | Surgical menopause | No contraception needed; confirm menopausal status | | Natural postmenopause | Confirm FSH/LH if under age 55 before assuming amenorrhea is permanent |

Who This Is Right For, and Who Should Avoid It

Postmenopausal Women With HSDD

This is the group with the strongest evidence base. The 2019 Global Consensus Statement and a 2019 systematic review and meta-analysis in Lancet Diabetes and Endocrinology found that transdermal testosterone improved the number of satisfying sexual events, sexual desire, arousal, and orgasm in postmenopausal women compared with placebo, with a mean increase of approximately 0.7 additional satisfying sexual events per month in 6-month trials. The effect size is modest but consistent.

Perimenopausal Women

Perimenopause brings erratic estrogen and progesterone fluctuation, and testosterone levels also begin to decline. Evidence in perimenopausal women is thinner than in fully postmenopausal women, and the hormonal volatility of this stage makes interpreting serum testosterone levels more difficult. Some clinicians prescribe low-dose testosterone for perimenopausal women with clear HSDD that does not respond to other interventions, but this is a judgment call made with incomplete trial data.

Premenopausal Women

The Global Consensus does not endorse testosterone use in premenopausal women because randomized trial data are lacking. Individual case-by-case decisions can still be made clinically, but women in their reproductive years should understand they are in territory where extrapolation, not direct evidence, is guiding the prescription.

Women Who Should Avoid Testosterone

Testosterone therapy is not appropriate if you:

• Are pregnant or trying to conceive without medical supervision and monitoring
• Are breastfeeding
• Have androgen-sensitive cancers (certain breast cancers, some ovarian cancers)
• Have untreated polycythemia
• Have active liver disease that impairs androgen metabolism
• Have PCOS with already elevated androgens unless specifically directed by your endocrinologist

Monitoring, Side Effects, and What "Safe" Actually Means at Female Doses

Monitoring Protocol

Based on the Global Consensus, the standard monitoring approach is:

1. Baseline total and free testosterone, SHBG, hematocrit
2. Repeat total/free testosterone at 3 to 6 weeks after starting
3. Target: upper limit of the normal premenopausal female range (total testosterone roughly 15 to 70 ng/dL depending on the assay)
4. Ongoing monitoring every 6 months once stable
5. Stop or reduce dose if levels exceed the upper limit of normal

Liquid chromatography-mass spectrometry (LC-MS/MS) assays are more accurate than immunoassay for measuring low female-range testosterone. Standard hospital immunoassays were calibrated for male ranges and can misread female levels.

Side Effects at Physiologic Doses

At doses that keep serum testosterone within the normal premenopausal range, androgenic side effects are uncommon but possible. These include acne, increased body hair, clitoral sensitivity changes, and, rarely, voice changes (which may be irreversible). The 2019 meta-analysis found no statistically significant increase in androgenic adverse events at physiologic doses compared with placebo over 6-month trial periods. Data beyond 24 months are sparse, and this is the honest answer to "is it safe long-term."

Cardiovascular signals (changes in lipid profiles) have been seen at supraphysiologic doses. At physiologic doses, the evidence does not show a consistent adverse lipid effect, but trial durations are short.

What We Do Not Know

Long-term breast cancer risk at physiologic female doses has not been established in a dedicated prospective trial. Observational data are reassuring but not definitive. Women with a personal or strong family history of hormone-receptor-positive breast cancer should have a detailed conversation with both their oncology team and prescribing clinician before starting testosterone.

Navigating a Prescription in the Current Regulatory Environment

If your clinician decides testosterone is appropriate for you, here is what the process looks like in practice.

Your prescriber will write a prescription for a compounded testosterone cream or gel, typically 0.5 to 2% strength, with instructions to apply a small volume to the inner arm, thigh, or vulvar tissue daily. The prescription goes to a 503A compounding pharmacy. Your insurance almost certainly will not cover it because there is no approved female product and no female-indication billing code that most plans recognize. Out-of-pocket costs range from roughly $30 to $80 per month depending on the pharmacy and formulation.

You should ask your pharmacy whether it is accredited by the Pharmacy Compounding Accreditation Board (PCAB), which signals adherence to quality standards beyond the minimum legal requirement.

If you have questions about whether your compounding pharmacy is operating legally, the FDA's compounding resource page lists registered 503B outsourcing facilities. For 503A pharmacies, your state board of pharmacy maintains a license database.